<a href="https://www.fiercebiotech.com/biotech/replimune-sheds-60-staff-after-fda-rejection-vows-continue-operations" hreflang="en">Replimune ramps up layoffs to cover 60% of workforce amid ongoing fallout of FDA rejection</a>
Replimune is laying off 161 employees, or 60% of its workforce, due to a recent FDA rejection of its lead melanoma drug, RP1, following an earlier rejection in July 2025. Despite the layoffs, the company plans to continue operations and is pursuing other treatment candidates in clinical trials.
The key takeaway from the Replimune situation is the critical importance of conducting "adequate and well-controlled" clinical trials to meet FDA standards, as failure to do so can lead to significant setbacks, including workforce reductions and financial instability. This underscores the necessity for healthtech and biotech professionals to prioritize robust trial design and clear communication with regulatory bodies to mitigate the risk of FDA rejections that can severely impact company operations.